Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFL8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $55,273
Award facts
- Contract value 100% obligated
- $55,272.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $55,272.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/mL syringes. The award, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, utilizes firm fixed-price pricing with no set-aside designation, enabling the contractor to compete on an unrestricted basis. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling value and extends through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy through which the DLA establishes regional prime vendor contractors to supply comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the DLA's Medical Supply Chain division, with a diverse product portfolio spanning oncology treatments, immunosuppressants, vaccines, and specialty pharmaceuticals. The award of XOLAIR, a biologic immunosuppressant agent, reflects the contractor's established performance in supplying critical specialty pharmaceutical products essential to military medical operations.
Quick answers
Who was awarded contract SPE2DR26FCFL8?
SPE2DR26FCFL8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCFL8 worth?
The government has obligated $55,273 on SPE2DR26FCFL8.
Is contract SPE2DR26FCFL8 an order under another contract?
Yes. SPE2DR26FCFL8 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFL8 competed?
The extent of competition for SPE2DR26FCFL8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award